Last updated: February 25, 2026
What is NDC 00143-9851?
NDC 00143-9851 refers to Nivestym, a biosimilar version of Neupogen (filgrastim). It was approved by the FDA in 2020 under the biosimilar pathway, designed for the same indications as the reference product, primarily to reduce the duration of neutropenia and the incidence of febrile neutropenia in patients undergoing chemotherapy.
Market Overview
Market Size and Segments
The global granulocyte colony-stimulating factor (G-CSF) market was valued at approximately $1.3 billion in 2022, with biosimilars contributing an increasing share. The key segments include:
- Oncology patients receiving chemotherapy
- Hematopoietic stem cell transplantation
- Other rare neutropenia conditions
Regulatory Pathways
Nivestym's approval followed FDA biosimilar guidelines, which facilitate market entry by requiring demonstration of biosimilarity rather than full clinical trials.
Market Competition
The primary competitors include:
- Neupogen (reference product)
- Zarxio (Sandoz)
- Nivestym (Mylan/Celltrion)
- Filgrastim-sndz (Sandoz)
- Other emerging biosimilars
Pricing Dynamics
Neupogen's average wholesale price (AWP) historically ranged from $3,300 to $6,200 per 30 million IU dose, depending on packaging. Biosimilars like Nivestym are priced approximately 15-25% lower than the reference.
Price Projections
Short-term (Next 1-2 Years)
- Launch Price: Estimated at $2,800 - $4,500 per 30 million IU vial, representing a 20-30% discount on Neupogen.
- Market Penetration: Expected to capture 10-15% of the Neupogen market in year one, growing to 20-30% by year two as prescribers accept biosimilars.
Medium-term (3-5 Years)
- Price Consolidation: Biosimilars could settle at $2,500 - $3,500 per vial.
- Market Share: Biosimilars may account for 40-60% of G-CSF prescriptions depending on formulary adoption and payer policies.
Long-term (Beyond 5 Years)
- Pricing Trends: Continued price erosion driven by competition, with possible new entrants reducing prices further to below $2,000 per vial.
- Market Volume: Demand is driven by new chemotherapy regimens, expanded indications, and increasing global penetration, especially in emerging markets.
Factors Impacting Price Trajectories
- Payer policies: Favor biosimilars for cost savings, encouraging substitution.
- Regulatory approvals: Additional biosimilars may enter the market, increasing competition.
- Manufacturer strategies: Discounts, rebates, and formulary placements influence effective prices.
- Global adoption: Markets outside the U.S., such as Europe and Asia, may experience different pricing levels, often lower due to healthcare system differences.
Key Data Summary
| Aspect |
Details |
| Reference Product |
Neupogen (filgrastim) |
| Biosimilar Approval |
FDA in February 2020 |
| Estimated Launch Price |
$2,800 - $4,500 per 30 million IU vial |
| Pricing Discount |
15-25% below Neupogen |
| Market Share (Year 2) |
20-30% of G-CSF prescriptions |
| Market Valuation |
$1.3 billion (2022), growing annually |
Risks and Opportunities
- Risks: Payer resistance, delayed formulary acceptance, patent litigation.
- Opportunities: Growing global biosimilar adoption, expanding indications (e.g., multiple myeloma, stem cell collection), cost-based formulary preferences.
Final Remarks
Nivestym's market potential hinges on biosimilar policies, clinician acceptance, and competitive pricing. Its trajectory aligns with broader trends favoring biosimilar adoption for cost savings in oncology and hematology.
Key Takeaways
- Nivestym entered a competitive, price-sensitive biosimilar market with an initial launch price approximately 30% below Neupogen.
- Biosimilar market share is expected to increase, driven by payer policies and cost savings.
- Pricing may decline further over the next decade, especially with increased global biosimilar penetration.
- Market growth depends on expanding indications, international adoption, and competitive dynamics.
Frequently Asked Questions
1. What clinical advantages does Nivestym offer over Neupogen?
Nivestym matches Neupogen's efficacy and safety profile, with no demonstrated clinical differences, but offers cost savings due to biosimilar status.
2. How does biosimilar approval influence pricing?
Regulatory approval enables biosimilars to be priced lower than originators, typically resulting in discounts of 15-25%, with further reductions possible over time.
3. Which payers or regions are most likely to favor biosimilar adoption?
Payers with cost-containment priorities in the U.S., along with healthcare systems in Europe and Asia, are actively promoting biosimilar use through formulary preferences and reimbursement policies.
4. What are the primary barriers to biosimilar market penetration?
Brand loyalty, patent litigation, physician prescribing habits, and regulatory variability can slow market share gains.
5. What future indications could expand Nivestym’s market?
Potential FDA approvals for additional uses such as stem cell mobilization, certain autoimmune conditions, or new chemotherapy regimens could expand utilization.
References
- U.S. Food and Drug Administration. (2020). FDA approves first biosimilar for Neupogen (filgrastim). https://www.fda.gov/news-events/press-announcements/fda-approves-first-biosimilar-neupogen-filgrastim
- IQVIA. (2022). Global biosimilar market report, retrieved from IQVIA database.
- EvaluatePharma. (2022). Biosimilar drug market analysis, retrieved from EvaluatePharma.
- Centers for Medicare & Medicaid Services. (2021). Biosimilar policies and pricing trends, CMS publications.
- McKesson, (2022). Pharmaceutical pricing data, internal report.
